Efficacy Results of a Trial of a Herpes Simplex Vaccine
New England Journal of Medicine2012Vol. 366(1), pp. 34–43
Citations Over TimeTop 1% of 2012 papers
Robert B. Belshe, Peter A. Leone, David I. Bernstein, Anna Wald, Myron J. Levin, Jack T. Stapleton, Iris Gorfinkel, Rhoda Morrow, Marian Ewell, Abbie Stokes‐Riner, Gary Dubin, Thomas C. Heineman, Joann Schulte, Carolyn Deal
Abstract
In a study population that was representative of the general population of HSV-1- and HSV-2-seronegative women, the investigational vaccine was effective in preventing HSV-1 genital disease and infection but not in preventing HSV-2 disease or infection. (Funded by the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline; ClinicalTrials.gov number, NCT00057330.).
Related Papers
- → Herpes simplex virus type 1 genital herpes in young women: current trend in Northern Finland(2014)21 cited
- Herpes genitalis in a student population.(1984)
- → A Case of Herpes Zoster With Genital Area Involvement Mistaken for Herpes Genitalis(2019)
- Characteristics of herpes genitalis in university women Características del herpes genital en mujeres universitarias.(2019)
- → Genital Herpes/Herpes Genitalis(2022)